(USD) | Mar 2024 | Q/Q |
---|---|---|
Revenue | 73MM | +10% |
Gross Profit | 59.1MM | - |
Cost Of Revenue | 13.9MM | +12% |
Operating Income | -5.5MM | -3% |
Operating Expenses | 64.6MM | - |
Net Income | -2.5MM | -2% |
R&D | 13.8MM | +6% |
G&A | 48.5MM | +10% |
Amortization | 2.2MM | -1% |
Interest Expense | 14K | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Castle Biosciences, Inc. ( NASDAQ:CSTL ) just released its latest first-quarter results and things are looking bullish...
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript May 4, 2024 Castle Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Castle Biosciences First Quarter 2024 Conference Call. As a remainder, today’s call […]
FRIENDSWOOD, Texas, May 03, 2024--Castle Biosciences will share new data supporting the utility of its DecisionDx®-SCC test at the ACMS Annual Meeting in Phoenix.
Comprehensive Analysis of Castle Biosciences' First Quarter Financial Performance
Castle Biosciences (CSTL) delivered earnings and revenue surprises of 75.68% and 6.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
FRIENDSWOOD, Texas, May 02, 2024--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2024.
FRIENDSWOOD, Texas, April 30, 2024--Castle Biosciences announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
FRIENDSWOOD, Texas, April 11, 2024--Castle will release its financial results for the first quarter ended March 31, 2024, after the close of market on Thursday, May 2, 2024.